Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
104 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Liver Cirrhosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Liver Cirrhosis - Pipeline Review, H2 2014', provides an overview of the Liver Cirrhosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Liver Cirrhosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Liver Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Liver Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Liver Cirrhosis Overview 9 Therapeutics Development 10 Pipeline Products for Liver Cirrhosis - Overview 10 Pipeline Products for Liver Cirrhosis - Comparative Analysis 11 Liver Cirrhosis - Therapeutics under Development by Companies 12 Liver Cirrhosis - Therapeutics under Investigation by Universities/Institutes 14 Liver Cirrhosis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Liver Cirrhosis - Products under Development by Companies 19 Liver Cirrhosis - Products under Investigation by Universities/Institutes 20 Liver Cirrhosis - Companies Involved in Therapeutics Development 21 ACROVIS biostructures GmbH 21 Alfa Wassermann S.p.A 22 Cellular Biomedicine Group, Inc. 23 Conatus Pharmaceuticals Inc. 24 Digna Biotech, S.L. 25 Galectin Therapeutics, Inc. 26 Gilead Sciences, Inc. 27 GNI Group Ltd. 28 Nitto Denko Corporation 29 Pacific Therapeutics Ltd. 30 PharmaIN Corporation 31 Pharmicell Co., Ltd. 32 Phenex Pharmaceuticals AG 33 S-Evans Biosciences, Inc. 34 Stelic Institute & Co. 35 Stempeutics Research Private Limited 36 Tobira Therapeutics, Inc. 37 Liver Cirrhosis - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Combination Products 39 Assessment by Target 40 Assessment by Mechanism of Action 42 Assessment by Route of Administration 44 Assessment by Molecule Type 46 Drug Profiles 48 (sofosbuvir + GS-5816) - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Cell Therapy for Liver Cirrhosis - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 cenicriviroc - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 DB-027 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 DB-036 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 emricasan - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 F-351 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 GR-MD-01 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Livercellgram - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Monoclonal Antibodies to Antagonize Transforming Growth Factor Beta 1 for HCV associated Liver Cirrhosis - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 ND-L02s0201 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 PTL-303 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Px-104 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 ReJoin - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 rifaximin - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Small Molecules for Liver Diseases - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Small Molecules to Inhibit EGFR for Gastrointestinal Disorders - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Stem Cell Therapy for Liver Cirrhosis - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Stem Cell Therapy for Liver Cirrhosis - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Stem Cell Therapy for Liver Cirrhosis - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Stem Cell Therapy for Liver Cirrhosis - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Stem Cell Therapy for Rheumatoid Arthritis and Liver Cirrhosis - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Stempeucel - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 STNM-04 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Thrombopoietin - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Undisclosed Peptide For Liver Cirrhosis - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Liver Cirrhosis - Recent Pipeline Updates 86 Liver Cirrhosis - Dormant Projects 96 Liver Cirrhosis - Discontinued Products 97 Liver Cirrhosis - Product Development Milestones 98 Featured News & Press Releases 98 Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting 98 Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting 99 Oct 06, 2014: New Anti-fibrosis Drug with Molecular Targeting DDS Starts Phase-1b Dosing for Cirrhosis Patients 100 Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension 100 Jan 20, 2011: Stempeutics Research's Stempeucel LC Recieves DCGI Clearance To Start Phase II Clinical Trial For Liver Cirrhosis 101 Nov 07, 2007: China Patent and Trademark Office Grants Patent for F351, GNI's Key Therapeutic Product for Liver Disease 102 Appendix 103 Methodology 103 Coverage 103 Secondary Research 103 Primary Research 103 Expert Panel Validation 103 Contact Us 104 Disclaimer 104
List of Tables Number of Products under Development for Liver Cirrhosis, H2 2014 10 Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Number of Products under Investigation by Universities/Institutes, H2 2014 14 Comparative Analysis by Late Stage Development, H2 2014 15 Comparative Analysis by Clinical Stage Development, H2 2014 16 Comparative Analysis by Early Stage Development, H2 2014 17 Comparative Analysis by Unknown Stage Development, H2 2014 18 Products under Development by Companies, H2 2014 19 Products under Investigation by Universities/Institutes, H2 2014 20 Liver Cirrhosis - Pipeline by ACROVIS biostructures GmbH, H2 2014 21 Liver Cirrhosis - Pipeline by Alfa Wassermann S.p.A, H2 2014 22 Liver Cirrhosis - Pipeline by Cellular Biomedicine Group, Inc., H2 2014 23 Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc., H2 2014 24 Liver Cirrhosis - Pipeline by Digna Biotech, S.L., H2 2014 25 Liver Cirrhosis - Pipeline by Galectin Therapeutics, Inc., H2 2014 26 Liver Cirrhosis - Pipeline by Gilead Sciences, Inc., H2 2014 27 Liver Cirrhosis - Pipeline by GNI Group Ltd., H2 2014 28 Liver Cirrhosis - Pipeline by Nitto Denko Corporation, H2 2014 29 Liver Cirrhosis - Pipeline by Pacific Therapeutics Ltd., H2 2014 30 Liver Cirrhosis - Pipeline by PharmaIN Corporation, H2 2014 31 Liver Cirrhosis - Pipeline by Pharmicell Co., Ltd., H2 2014 32 Liver Cirrhosis - Pipeline by Phenex Pharmaceuticals AG, H2 2014 33 Liver Cirrhosis - Pipeline by S-Evans Biosciences, Inc., H2 2014 34 Liver Cirrhosis - Pipeline by Stelic Institute & Co., H2 2014 35 Liver Cirrhosis - Pipeline by Stempeutics Research Private Limited, H2 2014 36 Liver Cirrhosis - Pipeline by Tobira Therapeutics, Inc., H2 2014 37 Assessment by Monotherapy Products, H2 2014 38 Assessment by Combination Products, H2 2014 39 Number of Products by Stage and Target, H2 2014 41 Number of Products by Stage and Mechanism of Action, H2 2014 43 Number of Products by Stage and Route of Administration, H2 2014 45 Number of Products by Stage and Molecule Type, H2 2014 47 Liver Cirrhosis Therapeutics - Recent Pipeline Updates, H2 2014 86 Liver Cirrhosis - Dormant Projects, H2 2014 96 Liver Cirrhosis - Discontinued Products, H2 2014 97
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.